CMAUP Plant Collective Molecular Activities

Plant Name: Mollugo pentaphylla

Collective Molecular Activities at 10μM Activity Cutoff

List of Human Proteins Collectively Targeted by the Plant

Target Activity Range: ≤ 10μM
Click Gene ID to Access Activity Profile of Individual Target

Target Class	Target Proteins

List of Human Cytochrome P450 Enzymes Affected by the Plant

Activity Range: ≤ 10μM
Click Gene ID to Access Activity Profile of Individual Enzyme

Cytochrome P450 Enzymes:

Detailed Information of Human Protein Targets

Protein Class	Gene ID	Protein Name	Uniprot ID	Target ChEMBL ID

Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)

Detailed Information of Enriched Gene Ontolgy

GO Type	GO Category	Enriched GO Terms	p-Value	Adjusted p-Value	Enriched Genes
BP	GO:0008152; metabolic process	GO:0097267; omega-hydroxylase P450 pathway	1.100E-12	1.662E-08	CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9
MF	GO:0005488; binding	GO:0019825; oxygen binding	4.098E-11	1.115E-07	CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4
MF	GO:0005488; binding	GO:0005506; iron ion binding	5.018E-11	1.214E-07	ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, XDH
BP	GO:0008152; metabolic process	GO:0019373; epoxygenase P450 pathway	8.789E-11	1.595E-07	CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9
MF	GO:0005488; binding	GO:0020037; heme binding	2.516E-08	2.382E-05	CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4
BP	GO:0008152; metabolic process	GO:0016098; monoterpenoid metabolic process	5.440E-08	4.387E-05	CYP1A2, CYP2C19, CYP2C9
BP	GO:0050896; response to stimulus	GO:0033993; response to lipid	4.941E-07	2.624E-04	AR, CA2, CYP1A1, CYP1A2, ESRRA, FLT3, HSD17B2, TP53, TYR
BP	GO:0050896; response to stimulus	GO:0042738; exogenous drug catabolic process	5.949E-07	3.084E-04	CYP1A2, CYP2C19, CYP2C9
BP	GO:0050896; response to stimulus	GO:1901700; response to oxygen-containing compound	8.033E-07	4.068E-04	AKR1B1, AR, CYP1A1, CYP1A2, CYP1B1, DAPK1, ESRRA, HSD17B2, NOX4, TP53, TYR
MF	GO:0003824; catalytic activity	GO:0004089; carbonate dehydratase activity	1.227E-06	5.936E-04	CA12, CA2, CA7
BP	GO:0008152; metabolic process	GO:0009404; toxin metabolic process	4.738E-06	1.984E-03	CYP1A1, CYP1A2, CYP1B1
MF	GO:0003824; catalytic activity	GO:0070330; aromatase activity	4.738E-06	1.984E-03	CYP1A1, CYP1A2, CYP1B1
BP	GO:0050896; response to stimulus	GO:0010038; response to metal ion	5.367E-06	2.142E-03	ALOX15, CA2, CYP1A1, CYP1A2, HIF1A, TP53
BP	GO:0009987; cellular process	GO:0032849; positive regulation of cellular pH reduction	6.074E-06	2.362E-03	CA2, CA7
BP	GO:0008152; metabolic process	GO:0017144; drug metabolic process	7.877E-06	2.869E-03	ABCC1, AKR1B1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9
BP	GO:0009987; cellular process	GO:0034599; cellular response to oxidative stress	7.905E-06	2.869E-03	AKR1B1, CYP1B1, DAPK1, NOX4, TP53
BP	GO:0008283; cell proliferation	GO:0042127; regulation of cell proliferation	8.712E-06	3.060E-03	AHR, AKR1B1, AR, CYP1B1, ESRRA, FLT3, HIF1A, LMNA, NOX4, TP53, XDH
BP	GO:0008152; metabolic process	GO:0006691; leukotriene metabolic process	1.193E-05	3.830E-03	ABCC1, ALOX15, ALOX5
BP	GO:0008152; metabolic process	GO:0018894; dibenzo-p-dioxin metabolic process	1.214E-05	3.830E-03	CYP1A1, CYP1A2
MF	GO:0003824; catalytic activity	GO:0034875; caffeine oxidase activity	1.214E-05	3.830E-03	CYP1A2, CYP2C9
MF	GO:0003824; catalytic activity	GO:0008395; steroid hydroxylase activity	1.584E-05	4.725E-03	CYP1A1, CYP2C19, CYP2C9
MF	GO:0003824; catalytic activity	GO:0009055; electron transfer activity	1.706E-05	5.021E-03	AKR1B1, CYP1A2, NOX4, XDH
BP	GO:0008152; metabolic process	GO:0006730; one-carbon metabolic process	1.886E-05	5.476E-03	CA12, CA2, CA7
BP	GO:0008152; metabolic process	GO:1901615; organic hydroxy compound metabolic process	2.361E-05	6.765E-03	AKR1B1, ALOX15, CYP1A1, CYP1B1, HIF1A, TYR
BP	GO:0032502; developmental process	GO:0048513; animal organ development	2.943E-05	8.216E-03	AR, CA2, CYP1A1, CYP1A2, ESRRA, FLT3, HIF1A, HSD17B2, TYR
BP	GO:0008152; metabolic process	GO:2001300; lipoxin metabolic process	3.029E-05	8.348E-03	ALOX15, ALOX5
BP	GO:0050896; response to stimulus	GO:0001666; response to hypoxia	3.184E-05	8.560E-03	CYP1A1, HIF1A, LMNA, NOX4, TP53
BP	GO:0051179; localization	GO:0015701; bicarbonate transport	3.472E-05	9.108E-03	CA12, CA2, CA7

Enriched KEGG Pathways of Target Proteins (Activity≤10μM)

Top 10, ordered by adjusted p-value

Detailed Information of Enriched KEGG Pathways

Pathway ID	Pathway Name	p-Value	Adjusted p-Value	Enriched Genes
hsa04913	Ovarian steroidogenesis_Homo sapiens_hsa04913	7.482E-09	5.762E-07	HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1
hsa00140	Steroid hormone biosynthesis_Homo sapiens_hsa00140	1.606E-08	6.182E-07	HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1
hsa01100	Metabolic pathways_Homo sapiens_hsa01100	3.978E-07	6.126E-06	CYP2C9; HSD17B1; ALOX5; HSD17B2; CYP1A2; ALOX15; CYP1A1; AKR1B1; CYP2C19; TYR; XDH
hsa00591	Linoleic acid metabolism_Homo sapiens_hsa00591	7.124E-08	1.799E-06	CYP2C9; CYP1A2; ALOX15; CYP2C19
hsa05204	Chemical carcinogenesis_Homo sapiens_hsa05204	9.344E-08	1.799E-06	CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP2C19
hsa00590	Arachidonic acid metabolism_Homo sapiens_hsa00590	1.621E-06	1.814E-05	CYP2C9; ALOX5; ALOX15; CYP2C19
hsa00980	Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980	3.129E-06	3.012E-05	CYP2C9; CYP1A2; CYP1A1; CYP1B1
hsa04726	Serotonergic synapse_Homo sapiens_hsa04726	1.720E-05	1.452E-04	CYP2C9; ALOX5; ALOX15; CYP2C19
hsa00380	Tryptophan metabolism_Homo sapiens_hsa00380	2.345E-05	1.642E-04	CYP1A2; CYP1A1; CYP1B1
hsa05200	Pathways in cancer_Homo sapiens_hsa05200	2.027E-04	1.040E-03	AR; FLT3; DAPK1; HIF1A; TP53
hsa05230	Central carbon metabolism in cancer_Homo sapiens_hsa05230	1.109E-04	6.567E-04	FLT3; TP53; HIF1A
hsa00830	Retinol metabolism_Homo sapiens_hsa00830	1.013E-04	6.499E-04	CYP2C9; CYP1A2; CYP1A1
hsa00982	Drug metabolism - cytochrome P450_Homo sapiens_hsa00982	1.210E-04	6.657E-04	CYP2C9; CYP1A2; CYP2C19
hsa00910	Nitrogen metabolism_Homo sapiens_hsa00910	1.649E-06	1.814E-05	CA12; CA2; CA7
hsa05219	Bladder cancer_Homo sapiens_hsa05219	1.498E-03	7.211E-03	DAPK1; TP53
hsa05215	Prostate cancer_Homo sapiens_hsa05215	6.865E-03	2.782E-02	AR; TP53
hsa05206	MicroRNAs in cancer_Homo sapiens_hsa05206	8.070E-03	3.107E-02	ABCC1; CYP1B1; TP53
hsa04976	Bile secretion_Homo sapiens_hsa04976	4.425E-03	1.893E-02	CA2; ABCG2
hsa02010	ABC transporters_Homo sapiens_hsa02010	1.724E-03	7.809E-03	ABCC1; ABCG2
hsa04919	Thyroid hormone signaling pathway_Homo sapiens_hsa04919	1.180E-02	4.266E-02	TP53; HIF1A
hsa04071	Sphingolipid signaling pathway_Homo sapiens_hsa04071	1.219E-02	4.266E-02	ABCC1; TP53
hsa00232	Caffeine metabolism_Homo sapiens_hsa00232	1.885E-05	1.452E-04	CYP1A2; XDH

Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)

Detailed Information of Human Diseases

ICD10 Disease Category	Disease Name	ICD10 Code	Linked Targets
E00-E89: Endocrine, nutritional and metabolic diseases	Hypogonadism	E23.0, E28.3, E29.1	AR
E00-E89: Endocrine, nutritional and metabolic diseases	Hyperuricaemia in gout	E79.0, M10	XDH
C00-D49: Neoplasms	Acute myeloid leukemia	C92.0	TP53; TP53; FLT3; FLT3
C00-D49: Neoplasms	Acute lymphoblastic leukemia	C91.0	FLT3
E00-E89: Endocrine, nutritional and metabolic diseases	Testosterone deficiency	E29.1	AR
I00-I99: Diseases of the circulatory system	Thrombosis	I80-I82	ALOX5
C00-D49: Neoplasms	CLL	NA	FLT3
C00-D49: Neoplasms	Cancer	C00-C96	AR; HIF1A; TP53; FLT3; FLT3
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Cachexia	R64	AR; ESRRA
M00-M99: Diseases of the musculoskeletal system and connective tissue	Muscle atrophy	M62.5	AR
C00-D49: Neoplasms	Multiple myeloma	C90	AHR
E00-E89: Endocrine, nutritional and metabolic diseases	Diabetic complication	E08-E13	AKR1B1
C00-D49: Neoplasms	Advanced prostate cancer	C61	AR
C00-D49: Neoplasms	Solid tumours	C00-D48	HIF1A; TP53; FLT3
E00-E89: Endocrine, nutritional and metabolic diseases	Hyperuricemia	E79.0	XDH
I00-I99: Diseases of the circulatory system	Cardiovascular disorder	I00-I99	AR
C00-D49: Neoplasms	Castration-resistant prostate cancer	C61	AR
E00-E89: Endocrine, nutritional and metabolic diseases	Non-insulin dependent diabetes	E11.9	ESRRA
C00-D49: Neoplasms	Gliosarcoma	NA	FLT3
C00-D49: Neoplasms	AML	NA	FLT3
J00-J99: Diseases of the respiratory system	Allergic rhinitis	J00, J30, J31.0, T78.4	ESRRA
L00-L99: Diseases of the skin and subcutaneous tissue	Alopecia	L65.9	AR
S00-T88: Injury, poisoning and certain other consequences of external causes	Allergy	T78.4	ALOX5
C00-D49: Neoplasms	Breast cancer	C50	AR; FLT3; FLT3
J00-J99: Diseases of the respiratory system	Airway inflammation	J00-J99	FLT3
K00-K95: Diseases of the digestive system	Alcoholic hepatitis	K70.1	AR
J00-J99: Diseases of the respiratory system	Rhinitis	J00, J30, J31.0	ALOX5
M00-M99: Diseases of the musculoskeletal system and connective tissue	Rheumatoid arthritis	M05-M06	ALOX5; TYR; AKR1B1; ESRRA
C00-D49: Neoplasms	Bladder cancer	C67	AR
J00-J99: Diseases of the respiratory system	Chronic obstructive pulmonary disease	J40-J44, J47	ALOX5
C00-D49: Neoplasms	Hormone refractory prostate cancer	C61	AR
C00-D49: Neoplasms	Pancreatic cancer	C25	FLT3
G00-G99: Diseases of the nervous system G00-G99	Pain	G64, G90.0, R52, G89	AR
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Schizophrenia	F20	ESRRA
A00-B99: Certain infectious and parasitic diseases	Human immunodeficiency virus infection	B20-B26	FLT3
H00-H59: Diseases of the eye and adnexa	Open-angle glaucoma	H40-H42	CA2
M00-M99: Diseases of the musculoskeletal system and connective tissue	Osteoporosis	M80-M81, Z79.890	AR
L00-L99: Diseases of the skin and subcutaneous tissue	Dermatitis	L20-L30	ALOX5; ESRRA
L00-L99: Diseases of the skin and subcutaneous tissue	Dermatological disease	L00-L99	AR; ESRRA
I00-I99: Diseases of the circulatory system	Pulmonary arterial hypertension	I27.0, I27.2	HIF1A
C00-D49: Neoplasms	Oral cavity cancer	C00-C08	TP53
L00-L99: Diseases of the skin and subcutaneous tissue	Pruritus	L29	ALOX5
N00-N99: Diseases of the genitourinary system	Prostate hyperplasia	N40	AR
C00-D49: Neoplasms	Prostate cancer	C61	AR; AR; FLT3
L00-L99: Diseases of the skin and subcutaneous tissue	Psoriasis	L40	ALOX5; FLT3
S00-T88: Injury, poisoning and certain other consequences of external causes	Toxicity	T36-T50, T51-T65	TP53
L00-L99: Diseases of the skin and subcutaneous tissue	Atopic dermatitis	L00-L99	ALOX5
C00-D49: Neoplasms	Lymphoma	C81-C86	HIF1A
NA: NA	Anaplastic mixed oligoastrocytoma	NA	FLT3
L00-L99: Diseases of the skin and subcutaneous tissue	Acne vulgaris	L70.0	AR; AR; ESRRA
E00-E89: Endocrine, nutritional and metabolic diseases	Diabetic cataract	E10.36, E11.36	AKR1B1
E00-E89: Endocrine, nutritional and metabolic diseases	Diabetic neuropathy	E11.40	AKR1B1
E00-E89: Endocrine, nutritional and metabolic diseases	Inflammation	E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89	ALOX5
C00-D49: Neoplasms	Inflammatory disease	C11, C44, K75.9, M00-M25	ALOX5
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Insomnia	F51.0, G47.0	CA2
E00-E89: Endocrine, nutritional and metabolic diseases	Diabetes	E23.2, N25.1	AKR1B1
C00-D49: Neoplasms	Myelofibrosis	C94.4, D47.4	FLT3
C00-D49: Neoplasms	Myeloid leukemia	C92	FLT3
A00-B99: Certain infectious and parasitic diseases	Lymphatic filariasis	B74	ALOX5
E00-E89: Endocrine, nutritional and metabolic diseases	Cystic fibrosis	E84	AR
M00-M99: Diseases of the musculoskeletal system and connective tissue	Osteoarthritis	M15-M19, M47	ALOX5
C00-D49: Neoplasms	Late-stage solid tumors	C00-C75, C7A, C7B, D10-D36, D3A	TP53
L00-L99: Diseases of the skin and subcutaneous tissue	Vitiligo	L80	TYR
E00-E89: Endocrine, nutritional and metabolic diseases	Male hormonal deficiencies	E20-E35	AR
H00-H59: Diseases of the eye and adnexa	Choroidal neovascularisation	H35	ESRRA
A00-B99: Certain infectious and parasitic diseases	Bacterial infections	A00-B99	CYP2C9
L00-L99: Diseases of the skin and subcutaneous tissue	Melasma	L81.1	TYR
C00-D49: Neoplasms	Melanoma	C43	TYR
H00-H59: Diseases of the eye and adnexa	Glaucoma	H40-H42	AKR1B1
NA: NA	GIST	NA	FLT3
C00-D49: Neoplasms	Glioblastoma	NA	FLT3
M00-M99: Diseases of the musculoskeletal system and connective tissue	Osteoporosis in post-menopausal women	M80-M81	AR
I00-I99: Diseases of the circulatory system	Atherosclerosis	I70	ALOX5
M00-M99: Diseases of the musculoskeletal system and connective tissue	Arthritis	M00-M25	ALOX5; ABCC1; ESRRA
J00-J99: Diseases of the respiratory system	Asthma	J45	ALOX5; ALOX5; ESRRA
NA: NA	Male hypogonadism	NA	AR
NA: NA	Edema	NA	CA2
I00-I99: Diseases of the circulatory system	Edema associated with congestive heart failure	I50, R60.9	CA2
G00-G99: Diseases of the nervous system G00-G99	Encephalopathy	G93.4	XDH
E00-E89: Endocrine, nutritional and metabolic diseases	Endocrine disease	E00-E35	AR
C00-D49: Neoplasms	Metastatic prostate cancer	C61	AR
C00-D49: Neoplasms	Leukemia	C90-C95	FLT3
M00-M99: Diseases of the musculoskeletal system and connective tissue	Gout	M10	XDH; AKR1B1; ABCC1; ABCC1
H60-H95: Diseases of the ear and mastoid process	Hearing disorder	H90.5	TP53
C00-D49: Neoplasms	Head and neck cancer	C07-C14, C32-C33	TP53; AKR1B1
I00-I99: Diseases of the circulatory system	Heart failure	I50	AR; XDH
K00-K95: Diseases of the digestive system	Duodenal ulcers	K25-K27	CA2
C00-D49: Neoplasms	Metastatic castration-resistant prostate cancer	C61	AR
C00-D49: Neoplasms	Hematological malignancies	C81-C86	TP53
NA: NA	Hematopoietic stem cell transplantation	NA	FLT3
C00-D49: Neoplasms	Colon cancer	C50	FLT3
C00-D49: Neoplasms	Colorectal cancer	C18-C21	TP53; FLT3
E00-E89: Endocrine, nutritional and metabolic diseases	Hormone deficiency	E00-E90	AR
NA: NA	HIV infections	NA	AHR
Z00-Z99: Factors influencing health status and contact with health services	Contraception	Z30	AR
K00-K95: Diseases of the digestive system	Gastrointestinal disease	K00-K93	ESRRA
I00-I99: Diseases of the circulatory system	High blood pressure	I10-I16	CA2
J00-J99: Diseases of the respiratory system	Respiratory disease	J00-J99	ALOX5
I00-I99: Diseases of the circulatory system	Renal artery disease	I70.1	TP53
A00-B99: Certain infectious and parasitic diseases	Fungal infections	B35-B49	ALOX5
C00-D49: Neoplasms	Female androgenresponsive recurrent mammary cancer	C50	AR

Data Section	Select to Download
1. General Info & Plant Usage & Geographical Distribution
2. Human Target Proteins
3. Target Gene Ontology
4. Target KEGG Pathway
5. Related Human Diseases